Next-Generation Biologics: R&D, Industry and Market 2014-2024

LONDON, Oct. 20, 2014 /True Blue Tribune/ –

Report Details

Many opportunities exist. And besides giving revenue predictions, that new analysis shows recent results, growth rates, and market shares. There you discover 94 tables, 55 charts, and two interviews with authorities in the biopharmaceuticals sector.
And the following sections explain what our new investigation gives you.
Analyses exclusive to that study, showing the most important commercial potentials
In our report you get data found nowhere else. Discover what’s really going on. Our forecasting system goes to the core of the biopharmaceutical industry’s sales potential like no other work, giving revenue predictions and their meanings.
That analysis benefits your plans, decisions, and influence by interpreting medical needs, R&D, and companies’ abilities. You hear what’s happening, then, assessing likely gains.

So find in those analyses where potential and money lie, also saving time, worry, and effort.

Prospects for the world market and submarkets – what’s possible for pharma biotechnology?

That work also splits its overall world market into leading products, showing where you could profit from new and improved biotech medicines.
Product forecasts for new forms, variations, and uses of biological therapy
How will individual drugs perform to 2024 at world level? Our report predicts revenues of seven top brands:
• Adcetris
• Kadcyla
• Gazyva
• Tresiba
• Afrezza
• Plegridy
• Eloctate.
There you find products and years with highest forecasted sales. And the report predicts those seven therapies will earn combined revenue of more than $10bn in 2024.
You also examine competitors. See what’s happening, then, understanding challenges, trends, competition, and opportunities. And here’s what that study’s author said:
“Next-generation biologics will address shortcomings in current therapies, including inconvenient dosing and concerns over side effects. Developmental trends include sustained release, for less-frequent dosing, and reformulations for oral and topical administration.”
That work also gives geographical revenue forecasts.

Healthcare in national markets – what outlooks for business in new biopharma products?

Market forces and issues – what affects biopharma developers, producers, and sellers?

And you explore these influences, among others:
• Disease incidence affecting demand for those more-developed medicines
• Improvements in therapeutic antibodies, including targeted cytotoxic therapies
• R&D pipelines – e.g. for immunotoxins – including agents in clinical development
• Biosimilar insulins likely from 2015 – transformation of that market
• Effects of rising incidence rates in cancer, diabetes, and cardiovascular disorders.

There discover what the future holds. You explore political, economic, social, and technological questions. See too how R&D helps companies benefit patients.
So you explore what progress, trends, and prospects mean. And discover what helps and what hinders players in that healthcare industry, affecting participants’ results.
Biological drug technology and applications – companies and 2018 market value
So what happens next? From 2014, novel and biosimilar treatments will benefit patients, doctors, and payers. Those advances will encourage investments, medical progress, and higher revenues from more-advanced biological drugs.

And our study predicts the next-generation biologics market will reach $12.17bn worldwide in 2018, and then multiply in revenues to 2024. See what’s possible and what you can gain.

Ways Next-Generation Biologics: R&D, Industry and Market 2014-2024 helps

Knowledge there found nowhere else, helping your searches, analyses, and planning

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

Miloslava Rezkova, Gold Medal Olympic High Jumper, Dies at 64

Miloslava Rezkova, a Czech high jumper who at 18 pulled off a major upset when she beat two better-known Russians to win a gold medal at the 1968 Olympics in Mexico City, setting off a burst of national pride by…

Osteoporosis Treatment and Prevention: World Drug Market Forecast 2014-2024 & Future Prospects for Leading Companies

LONDON, Oct. 20, 2014 /True Blue Tribune/ – Report Details Forecasts to 2024 and other analyses explain and predict that pharma market Forecasting of that world market and its main segments Predictions of leading treatments’ sales Healthcare in national markets…

Antiemetic Drugs: World Industry and Market Analysis 2014-2024

LONDON, Oct. 20, 2014 /True Blue Tribune/ – Report Details Forecasts to 2024 and other analyses explain and predict that pharma market Forecasting of that world market and its main segments Predictions of leading treatments’ sales Healthcare in national markets…

Connecture, Inc. Files Registration Statement For Proposed Initial Public Offering

BROOKFIELD, Wis., Oct. 20, 2014 /True Blue Tribune/ — Connecture, Inc. (Connecture), a provider of web-based information systems used to create health insurance marketplaces, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities…

Avoid the Danger of Opioid Painkillers through Laser Back Surgery

LOS ANGELES, Oct. 20, 2014 /True Blue Tribune/ — Chronic pain is a major concern in our modern society, with more than 31% of U.S. adults suffering from some type of neck or back pain, according to a 2012 Gallup-Healthways…

Pharma Leader Series: Top Stem Cell Technology Companies 2014-2024

LONDON, Oct.20, 2014 /True Blue Tribune/ – Report Details Stem cell developers and producers – discover companies’ R&D and revenue prospects Who are the top stem cell developers and producers? And what are their sales potentials? Visiongain’s new report shows…

Opera Star Joyce DiDonato, Kansas City Native, Is Left Off Early Anthem Roster

In the days leading up to Tuesday night’s World Series curtain-raiser, the burning question in Kansas City was not whether the Royals’ ace, James Shields, would survive to pitch the sixth inning, or if the road to ruin is paved…

Defamation Lawsuit Against Shelly Sterling Is Dismissed

LOS ANGELES — A judge reversed course Monday and dismissed a defamation lawsuit by Donald Sterling’s mistress against the estranged wife of the former Los Angeles Clippers owner. Judge Richard Fruin issued a tentative ruling last week saying he planned…

Zuckerberg Seeks Revenge As Facebook Sues Lawyers For Paul Ceglia

Back in 2011, my colleague Kashmir Hill wrote a piece titled “Paul Ceglia to Facebook and Mark Zuckerberg: Bring It On.” Facebook did just that, digging up evidence the convicted felon had a history of dubious financial behavior and may…